Position in JBIO
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,221,900
-$2,785,992 QoQ
Shares Held
145,000
-66.1% QoQ
Ownership
0.228%
of shares outstanding
% of Portfolio
0.30%
of 13F equity value
Holder Rank
#46
of 153 holders
Holding Since
Jun 2024
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JBIO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Opaleye Management Inc. holds $678,840,611 across 50 Biotechnology names. JBIO ranks #37 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IRON |
Disc Medicine, Inc.
|
855,000 | $62,534,700 | |
| 2 | URGN |
UroGen Pharma Ltd.
|
1,439,996 | $52,991,852 | |
| 3 | APGE |
Apogee Therapeutics, Inc.
|
390,000 | $51,764,700 | |
| 4 | MGTX |
MeiraGTx Holdings plc
|
3,550,000 | $47,960,500 | |
| 5 | SLGL |
Sol-Gel Technologies Ltd.
|
500,000 | $37,070,000 | |
| 6 | RZLT |
Rezolute, Inc.
|
6,300,000 | $32,760,000 | |
| 7 | TGTX |
Tg Therapeutics, Inc.
|
535,000 | $29,392,900 | |
| 8 | IMMX |
Immix Biopharma, Inc.
|
2,345,000 | $24,176,950 |
All Filings in JBIO
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,221,900 | 145,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $6,007,892 | 427,608 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $6,597,991 | 427,608 | Shares | Sole | 2026-04-13 | |
| 2024-09-30 AVTE | — | 440,000 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 AVTE | — | 440,000 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||